Page 76 - 81_02

Carmen Avendaño
6. c) Agnandji ST, Lell B, Fernandes JF, et al. A
Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in
African Infants. New England Journal of Medicine
2012; 367: 2284-95.
11. Plassmeyer ML, Reiter K, Shimp RL Jr, et al. Structure
of the Plasmodium falciparum circumsporozoite
protein, a leading malaria vaccine candidate. J Biol
Chem 2009; 284: 26951-63.
12. Coppi A, Pinzón-Ortiz C, Hunter Ch. The Plasmodium
circumsporozoite protein is proteolytically processed
during cell invasion. JEM 2005; 201: 27-33.
13. Aldrich C, Magín A, Emiliani C, et al. Roles of the
Amino Terminal Region and Repeat Region of the
Plasmodium berghei Circumsporozoite Protein in
Parasite Infectivity. PLoS One 2012; 7: e32524.
14. Coffman RL, Sher A, Seder RA. Vaccine adjuvants:
putting innate immunity to work. Immunity 2010;
33:492-503.
15. Myers KR, Truchot AT, Ward J, et al. A critical
determinant of lipid A endotoxic activity. In:
Nowotny A, Spitzer JJ, Ziegler EJ, editors. Cellular
and Molecular Aspects of Endotoxin Reactions.
Amsterdam: Elsevier Sciences Publishers B V; 1990.
pp. 145-56.
16. Ragupathi G, Gardner JR, Livingston PO, Gin DY.
Natural and synthetic saponin adjuvant QS-21 for
vaccines against cancer. Expert Rev Vaccines 2011;
10:463-70.
17. Chea EK, Fernández-Tejada A, Damani P, et al.
Synthesis and Preclinical Evaluation of QS-21
Variants Leading to Simplified Vaccine Adjuvants
and Mechanistic Probes. J Am Chem Soc 2012, 134:
13448-57.
18. Para el registro de este ensayo ver: ClinicalTrials.gov,
número NCT00866619.
19. a) RTS,S Clinical Trials Partnership. First results of
Phase 3 trial of RTS,S/AS01 malaria vaccine in
African children. N Engl J Med 2011; 365: 1863-75.
b) RTS,S Clinical Trials Partnership. A Phase 3 trial
of RTS,S/AS01 malaria vaccine in African infants. N
Engl J Med 2012; 367: 2284-95.
20. Foquet L, Hermsen C, van Gemert G-J, et al. Vaccine-
induced monoclonal antibodies targeting
circumsporozoite protein prevent Plasmodium
falciparum infection. J Clin Invest 2014; 124: 140-4.
21. RTS,S Clinical Trials Partnership. Efficacy and safety
of the RTS,S/AS01 malaria vaccine during 18 months
after vaccination: a Phase 3 randomized, controlled
trial in children and young infants at 11 African sites. 29. a) Sibley CH, Ringwald P. A database of antimalarial
PLoS Med 2014; 11: e1001685.
22. Greenwood BM y otros muchos autores. Efficacy and
safety of RTS,S/AS01 malaria vaccine with or without
a booster dose in infants and children in Africa: final
results of a Phase 3, individually randomised,
controlled trial. Lancet 2015; S0140-6736(15)60721-
8. 23. Bojang K, Milligan P, Pinder M, et al. Five-year
safety and immunogenicity of GlaxoSmithKline’s
156
candidate malaria vaccine RTS,S/AS02 following
administration to semi-immune adult men living in a
malaria-endemic region of The Gambia. Hum Vaccin
2009; 5: 242-47.
24. WHO Initiative for vaccine research/global malaria
programme joint technical expert group (JTEG) on
malaria vaccines entering pivotal Phase 3 trials &
beyond (established April 2009).
http://www.who.int/immunization/research/committee
s/jteg/en (accessed April 22, 2015).
25. Keiser J, Utzinger J, Premji Z, Yamagata Y, Singer
BH. Acridine Orange for malaria diagnosis: its
diagnostic performance, its promotion and
implementation in Tanzania, and the implications for
malaria control. Ann Trop Med Parasitol 2002; 96:
643-54.
26. Spielman A, Perrone JB, Teklehaimanot A, et al.
Malaria Diagnosis by Direct Observations of
Centrifuged Samples of Blood. Am J Trop Med Hyg
1988; 39: 337-42.
27. Engelbrecht F, Tögel E, Beck HP. Analysis of
Plasmodium falciparum infections in a village
community in Northern Nigeria: determination of
msp2 genotypes and parasite-specific IgG responses.
Acta Tropica 2000; 74: 63-71.
28. Ochola LB, Vounatsou P, Smith T, Mabaso MLH,
Newton CRJC. The reliability of diagnostic
techniques in the diagnosis and management of
malaria in the absence of a gold standard. The Lancet
Infectious Diseases 2006; 6: 582-88.
drug resistance. Malar J 2006; 5: 48-56. b) Alonso PL,
Brown G, Arévalo-Herrera M, et al. A research
agenda to underpin malaria eradication. PLOS Med
2011; 8: e1000406. c) Petersen I, Eastman R, Lanzar
M. Drug-resistant malaria: molecular mechanisms and
implications for public health. FEBS Lett 2011; 585,
1551-62.
30. Algunos comentarios acerca de su uso y mecanismos
de acción pueden encontrarse en: a) Avendaño C. La
innovación farmacéutica. Comentarios sobre tres
noticias. Anal Real Acad Nac Farm 2005; 71: 873-
904. b) Avendaño C. Los productos naturales en la
búsqueda de nuevos fármacos. Una visión de
conjunto. Anal Real Acad Nac Farm 2011; 77: 15-35.
31. White NJ. The Treatment of Malaria. N Engl J Med
1996; 335: 800-06.
32. Ver por ejemplo: Njhomaer S. Is sulphadoxine-
pyrimethamine (SP) still useful as the first-line
antimalarial drug in Malawi or it must be quickly
withdrawn from the antimalarial repertoire?. Malawi
Med J 2007; 19: 37-38.
33. Ver por ejemplo: Winstaley P. Modern
chemotherapeutic options for malaria. Lancet Infect
Dis 2001; 1: 242-50.
34. Robert A, BenoitVical F, DechyCabaret O, Meunier B.
From classical antimalarial drugs to new compounds
@Real Academia Nacional de Farmacia. Spain